Protein / target
DNA topoisomerase 4 subunit A
Protein at a glance
Biological role
ATP binding
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Topoisomerase IV is essential for chromosome segregation; it is the principal protein responsible for decatenating newly replicated chromosomes.
View complete UniProt function annotationHide complete annotation
Topoisomerase IV is essential for chromosome segregation; it is the principal protein responsible for decatenating newly replicated chromosomes (PubMed:9334322). It relaxes supercoiled DNA (PubMed:12269820, PubMed:16023670, PubMed:21300644). MukB stimulates the relaxation activity of topoisomerase IV and also has a modest effect on decatenation (PubMed:20921377)
Subcellular location
Domains and Gene Ontology detail (13)Hide
Domains & features
Gene Ontology
- Cchromosome
- Ccytoplasm
- Ccytosol
- CDNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complex
- Cextrinsic component of plasma membrane
- FATP binding
- FDNA binding
- FDNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activity
- Pchromosome segregation
- PDNA topological change
- Pplasmid partitioning
- Psister chromatid cohesion
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Topoisomerase IV inhibitor
Indicated for Bacterial Infections, Eye Infections, Gonorrhea, Infections
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 2 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Label change
Label change: CIPROFLOXACIN (ANDA076558)
- Label change
Label change: CIPROFLOXACIN (ANDA076794)
- New publicationGlobal diversity and antimicrobial resistance of typhoid fever pathogens: Insights from a meta-analysis of 13,000 <i>Salmonella</i> Typhi genomes.
- Label change
Label change: CIPROFLOXACIN (ANDA076558)
- Label change
Label change: CIPROFLOXACIN (ANDA076558)
- Label change
Label change: CIPROFLOXACIN (ANDA076558)
- Label change
Label change: CIPROFLOXACIN (ANDA076558)
- Label change
Label change: CIPROFLOXACIN (ANDA076558)
- Safety communication
Drug Safety Update: Norfloxacin: restricted use in urinary infections
- New publicationCefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial.
- New publicationComparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.
- New publicationThe pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.